Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vimian Group AB (DE:0V0)
FRANKFURT:0V0
Holding DE:0V0?
Track your performance easily
0V0 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.97 - €4.12
Previous Close€3.74
Volume0.00
Average Volume (3M)7.20K
Market Cap
€1.97B
Enterprise Value€2.22B
Total Cash (Recent Filing)€51.18M
Total Debt (Recent Filing)€296.79M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Feb 13, 2025EPS Estimate
€0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume7,204
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)4.84
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.28Price Target Upside-12.30% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Vimian Group AB News
Bulls Say, Bears Say
Bulls Say
Business GrowthSpecialty Pharma and Veterinary Services grew 11% and 15% organically, respectively.
Financial CompensationThe seller will compensate Vimian for his entire pro rata share, which amounts to 37% of the USD 70m settlement payment, corresponding to a total value of USD 26m.
Settlement AgreementVimian announced it has reached a third settlement agreement with the sellers of VOI in the indemnification process related to the patent dispute with DePuy Synthes.
Bears Say
Earnings ReportVimian delivered a weak Q1 report, with net sales increasing only 4% y-o-y to EUR 91.3m, missing consensus by 3%.
Financial PerformanceAdjusted EBITA declined 8% y-o-y to EUR 24.1m, missing consensus estimates by 8% due to the smaller AOP in MedTech.
Organic GrowthOrganic growth amounted to just 1% on a group level, driven by a 12% decline in MedTech as a result of the company's decision to reduce the annual ordering program.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.71% Mutual Funds
― Other Institutional Investors
98.75% Public Companies and
Individual Investors
0V0 FAQ
What was Vimian Group AB’s price range in the past 12 months?
Vimian Group AB lowest stock price was €1.97 and its highest was €4.12 in the past 12 months.
What is Vimian Group AB’s market cap?
Currently, no data Available
When is Vimian Group AB’s upcoming earnings report date?
Vimian Group AB’s upcoming earnings report date is Feb 13, 2025 which is in 103 days.
How were Vimian Group AB’s earnings last quarter?
Vimian Group AB released its earnings results on Oct 24, 2024. The company reported €0.01 earnings per share for the quarter, missing the consensus estimate of €0.021 by -€0.011.
Is Vimian Group AB overvalued?
According to Wall Street analysts Vimian Group AB’s price is currently Overvalued.
Does Vimian Group AB pay dividends?
Vimian Group AB does not currently pay dividends.
What is Vimian Group AB’s EPS estimate?
Vimian Group AB’s EPS estimate is €0.03.
How many shares outstanding does Vimian Group AB have?
Vimian Group AB has 517,032,350 shares outstanding.
What happened to Vimian Group AB’s price movement after its last earnings report?
Vimian Group AB reported an EPS of €0.01 in its last earnings report, missing expectations of €0.021. Following the earnings report the stock price went up 0.277%.
Which hedge fund is a major shareholder of Vimian Group AB?
Currently, no hedge funds are holding shares in DE:0V0
---
Vimian Group AB Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.24%
12-Months-Change
Fundamentals
Return on Equity
-0.03%
Trailing 12-Months
Asset Growth
4.32%
Trailing 12-Months
Company Description
Vimian Group AB
Vimian Group AB specializes in the areas of animal health such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a strong position within allergy, dermatology, otology and specialised nutrition.
---
0V0 Stock 12 Month Forecast
Average Price Target
€3.28
▼(-12.30% Downside)
Technical Analysis
Best Analysts Covering 0V0
1 Year
1 Year Success Rate
9/9 ratings generated profit
1 Year Average Return
+36.67%
reiterated a buy rating 10 days ago
Copying Adela Dashian's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +36.67% per trade.
---